![logo](/logos/NRIX.webp)
Nurix Therapeutics, Inc.
NASDAQ:NRIX
23.33 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Nurix Therapeutics, Inc. |
Symbool | NRIX |
Munteenheid | USD |
Prijs | 23.33 |
Beurswaarde | 1,502,729,627 |
Dividendpercentage | 0% |
52-weken bereik | 4.22 - 26.123 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Website | https://www.nurixtx.com |
An error occurred while fetching data.
Over Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)